Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Pharmaceutical CDMO Market, by Region, 2020-2030 (USD Billion)
1.2.2. Pharmaceutical CDMO Market, by Product, 2020-2030 (USD Billion)
1.2.3. Pharmaceutical CDMO Market, by Workflow, 2020-2030 (USD Billion)
1.2.4. Pharmaceutical CDMO Market, by Application, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Pharmaceutical CDMO Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Pharmaceutical CDMO Market Dynamics
3.1. Pharmaceutical CDMO Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing demand for biopharmaceuticals
3.1.1.2. Increasing Cases of Cancer across the Globe
3.1.2. Market Challenges
3.1.2.1. High Cost of Pharmaceutical CDMO
3.1.3. Market Opportunities
3.1.3.1. Technological advancements in manufacturing
Chapter 4. Global Pharmaceutical CDMO Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Pharmaceutical CDMO Market, by Product
5.1. Market Snapshot
5.2. Global Pharmaceutical CDMO Market by Product, Performance – Potential Analysis
5.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
5.4. Pharmaceutical CDMO Market, Sub Segment Analysis
5.4.1. API
5.4.2. Drug
Chapter 6. Global Pharmaceutical CDMO Market, by Workflow
6.1. Market Snapshot
6.2. Global Pharmaceutical CDMO Market by Workflow, Performance – Potential Analysis
6.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Workflow 2020-2030 (USD Billion)
6.4. Pharmaceutical CDMO Market, Sub Segment Analysis
6.4.1. Clinical
6.4.2. Commercial
Chapter 7. Global Pharmaceutical CDMO Market, by Application
7.1. Market Snapshot
7.2. Global Pharmaceutical CDMO Market by Application, Performance – Potential Analysis
7.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
7.4. Pharmaceutical CDMO Market, Sub Segment Analysis
7.4.1. Oncology
7.4.2. Hormonal
7.4.3. Glaucoma
7.4.4. Cardiovascular Disease
7.4.5. Diabetes
7.4.6. Others
Chapter 8. Global Pharmaceutical CDMO Market, Regional Analysis
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Pharmaceutical CDMO Market, Regional Market Snapshot
8.4. North America Pharmaceutical CDMO Market
8.4.1. U.S. Pharmaceutical CDMO Market
8.4.1.1. Product breakdown estimates & forecasts, 2020-2030
8.4.1.2. Workflow breakdown estimates & forecasts, 2020-2030
8.4.1.3. Application breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Pharmaceutical CDMO Market
8.5. Europe Pharmaceutical CDMO Market Snapshot
8.5.1. U.K. Pharmaceutical CDMO Market
8.5.2. Germany Pharmaceutical CDMO Market
8.5.3. France Pharmaceutical CDMO Market
8.5.4. Spain Pharmaceutical CDMO Market
8.5.5. Italy Pharmaceutical CDMO Market
8.5.6. Rest of Europe Pharmaceutical CDMO Market
8.6. Asia-Pacific Pharmaceutical CDMO Market Snapshot
8.6.1. China Pharmaceutical CDMO Market
8.6.2. India Pharmaceutical CDMO Market
8.6.3. Japan Pharmaceutical CDMO Market
8.6.4. Australia Pharmaceutical CDMO Market
8.6.5. South Korea Pharmaceutical CDMO Market
8.6.6. Rest of Asia Pacific Pharmaceutical CDMO Market
8.7. Latin America Pharmaceutical CDMO Market Snapshot
8.7.1. Brazil Pharmaceutical CDMO Market
8.7.2. Mexico Pharmaceutical CDMO Market
8.8. Middle East & Africa Pharmaceutical CDMO Market
8.8.1. Saudi Arabia Pharmaceutical CDMO Market
8.8.2. South Africa Pharmaceutical CDMO Market
8.8.3. Rest of Middle East & Africa Pharmaceutical CDMO Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Bushu Pharmaceuticals Ltd.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Nipro Corporation
9.3.3. Thermo Fisher Scientific Inc.
9.3.4. Samsung Biologics
9.3.5. Laboratory Corporation of America Holdings
9.3.6. Siegfried Holding Ag
9.3.7. Catalent, Inc
9.3.8. Lonza Group AG
9.3.9. Recipharm Ab
9.3.10. Piramal Pharma Solutions
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/